Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

Study; and the use of pharmacotherapy to treat obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; the development plan for Empatic; Orexigen's ability to enter into a collaborative partnersh
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Inc. (NASDAQ: CYBX ), a global leader in ... announced it will participate in the 33 rd  Annual ... San Francisco . Dan ... at 11:00 AM Pacific Time.  A live audio webcast of ... Relations link on the Cyberonics home page at www.cyberonics.com ...
(Date:12/22/2014)... SAN DIEGO , Dec. 22, 2014  Pfenex ... Px563L, Pfenex,s recombinant anthrax vaccine, has been filed and ... additional funding provided by the Department of Health and ... Development Authority (BARDA). "We are extremely pleased ... anthrax vaccine, Px563L.  This represents a significant milestone in ...
(Date:12/19/2014)... 2014  Newport Corporation (NASDAQ: NEWP ... joined the company,s Board of Directors.  Dr. Kadia ... director of Evans Analytical Group, a leading global ... services to companies in a wide range of ... Analytical Group, Dr. Kadia spent nine years with ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
(Date:12/22/2014)... December 22, 2014 As early as ... can present in the form of “jowls." The dreaded ... start of the marionette line or smile lines. Aging ... diligent skincare, but as the deep facial tissues descend, ... all synthetic fillers that can be used under the ...
(Date:12/22/2014)... 22, 2014 On December 22, 2014, ... Pastor Gordon Cashwell for an episode to celebrate Christmas. ... “Why is it so important to you that we ... replies, “We all should respect who Jesus was. I ... on Christian beliefs. That means that on Jesus’ birthday ...
(Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
(Date:12/22/2014)... 22, 2014 Give a loved one ... gift of health and vitality. , For a limited ... top-selling anti-aging formulas in special Holiday Wellness gift packages ... , Each bottle contains cutting-edge, proven nutritional support ... work as well as we age. , ...
(Date:12/22/2014)... December 22, 2014 7,178 small business ... of Black Friday shopping and opted instead to join ... education company, for their 5th annual “Black Friday Boot ... just $7 to attend the 5 hour online training ... promptly donated to support two Central Texas based charities ...
Breaking Medicine News(10 mins):Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3
... year, approximately 4,500 children in America are diagnosed with leukemia, ... cancer of the blood, it is the most common cancer ... of 10 cases of childhood leukemia, so parents can still ... Izraeli of Tel Aviv University,s Sackler School of Medicine and ...
... with America,s kids, , TUESDAY, July 28 (HealthDay News) -- ... tag of $147 billion per year in direct medical costs, ... at a national conference Tuesday in Washington, DC. , "To ... that all cancers combined cost our health care system $93 ...
... , CHICAGO, July 28 Underscoring the need for ... Association (AMA) is running an ad today emphasizing common ground on health ... The AMA ad runs nationally today in the Chicago Tribune , ... Online advertising will run in various medical trade publications. ...
... , LEBANON, Tenn., July 28 Health Connect Partners, ... has been named the title sponsor of its 2009 Fall Hospital ... Conference is expecting up to 200 directors of pharmacy from some ... addition to educational sessions led by healthcare industry experts, the Hospital ...
... , , FRIENDSWOOD, Texas, ... which develops, manages and owns faith-based senior living facilities, today announced ... Inc. for the development of a new senior living facility in ... Heights , an 82-unit, $10 million senior living facility, should be ...
... , ANN ARBOR, Mich., July 28 ... were at greater risk for a wide range of medical conditions than ... , The study analyzed de-identified insurance claims for more than ... and an interactive graphic charting bipolar patients, risk of comorbid disorders ...
Cached Medicine News:Health News:New drug for children with high-risk leukemia 2Health News:More Can Be Done to Slow Obesity's Toll on Health: Experts 2Health News:More Can Be Done to Slow Obesity's Toll on Health: Experts 3Health News:More Can Be Done to Slow Obesity's Toll on Health: Experts 4Health News:New AMA Ad Emphasizes Common Ground on Health Reform, Shares Vision to Fix Broken System 2Health News:Cardinal Health Announced as Title Sponsor of the Health Connect Partners' 2009 Fall Hospital Pharmacy Conference 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 3Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 4Health News:Patients With Bipolar Disorder at Increased Risk for Wide Range of Health Problems, Thomson Reuters Study Finds 2
Pediatric size. Loops retract lids. Polished finish....
Open ring design with shaft angled at 45 degrees. Blunt teeth. Round knurled handle with dull finish....
Fixation ring with atraumatic teeth provides excellent stabilization and pressure on globe. Round knurled handle with dull finish....
... Designed to fixate the eye ... two-sided ring can easily be ... or smooth side on the ... to the eye to increase ...
Medicine Products: